Bausch + Lomb Co. (NYSE:BLCO – Free Report) – Equities research analysts at HC Wainwright decreased their Q1 2025 EPS estimates for Bausch + Lomb in a research note issued on Friday, February 21st. HC ...
H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...
Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (NasdaqGM:VERI) with a Buy ...
PepGen (PEPG) announced initial data from the FREEDOM-DM1 trial highlighting a dose- dependent robust increase in the splicing correction at 28 ...
HC Wainwright reiterated their neutral rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research report sent to ...
H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...
Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...
will participate in the H.C. Wainwright 3 rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. (PRNewsfoto/CARISMA Therapeutics Inc.) An audio webcast of the event ...
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...
In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results